San Diego-centered Viking Therapeutics marked alone as a significant competitor within the weight loss drug market in February following revealing promising facts from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the company unv